These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11856618)

  • 41. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
    Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
    Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of chronic hepatitis B in HIV co-infected patients.
    Guan R
    Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
    Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
    Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
    Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient.
    Gouskos T; Wightman F; Chang J; Earnest-Silveira L; Sasadeusz J; Lewin SR; Torresi J
    AIDS; 2004 Aug; 18(12):1734-7. PubMed ID: 15280788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
    Bessesen M; Ives D; Condreay L; Lawrence S; Sherman KE
    Clin Infect Dis; 1999 May; 28(5):1032-5. PubMed ID: 10452630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
    Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
    Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy.
    Honkoop P; de Man RA; Niesters HG; Main J; Nevens F; Thomas HC; Fevery J; Tyrrell DL; Schalm SW
    J Viral Hepat; 1998 Sep; 5(5):307-12. PubMed ID: 9795914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients.
    Mese S; Arikan M; Cakiris A; Abaci N; Gumus E; Kursun O; Onel D; Ustek D; Kaymakoglu S; Badur S; Yenen OS; Bozkaya E
    J Gen Virol; 2013 Dec; 94(Pt 12):2729-2738. PubMed ID: 24045109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J; Bani-Sadr F; Gassin M; Raffi F
    Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B.
    Akyildiz M; Gunsar F; Ersoz G; Karasu Z; Ilter T; Batur Y; Akarca U
    Dig Dis Sci; 2007 Dec; 52(12):3444-7. PubMed ID: 17431777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.
    Thabut D; Thibault V; Bernard-Chabert B; Mouquet C; Di Martino V; Le Calvez S; Opolon P; Benhamou Y; Bitker MO; Poynard T
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1367-73. PubMed ID: 15618847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.